p38 is a member of the mitogen-activated protein (MAP) kinase superfamily and mediates intracellular signal transduction. Recent studies suggest that p38 is involved in apoptotic signaling in several cell types, including neurons. In the mammalian retina, ϳ50% of the retinal ganglion cells (RGCs) die by apoptosis during development. Additionally, transection of the optic nerve close to the eye bulb causes apoptotic cell death of RGCs in adulthood. We investigated the role of p38 in axotomyinduced apoptosis of RGCs. One day after axotomy, activated (phosphorylated) p38 was visualized by immunocytochemistry in the nuclei of RGCs, but not in control retinas. Phosphorylated p38 was first detected on immunoblots 12 hr after axotomy, reached a maximum at 1 d, and then decreased. To investigate possible roles of p38 in RGC death, a p38 MAP kinase inhibitor, SB203580, was administered intravitreally at the time of axotomy and repeated at 5 and 10 d. Assayed 14 d after axotomy, SB203580 increased the number of surviving RGCs in a dosedependent manner (the minimum effective concentration was 1.6 M). Furthermore, MK801, a selective inhibitor of NMDA receptors, not only showed protective effects against RGC apoptosis but also attenuated p38 MAP kinase activation in a dose-dependent manner. Our findings imply that p38 is in the signaling pathway to RGC apoptosis mediated by glutamate neurotoxicity through NMDA receptors after damage to the optic nerve. p38 inhibitors could be potentially useful for the treatment of optic nerve trauma and neurodegenerative diseases that affect RGCs, such as glaucoma.
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Mitogen-activated protein (MAP) kinases are serine/threonine kinases and play an instrumental role in signal transduction from the cell surface to the nucleus. The mammalian MAP kinases can be subdivided into extracellular signal-regulated kinases (ERK), Jun N-terminal kinases (JNK), and p38 MAP kinases (p38). p38 is activated by dual phosphorylation on a Thr-Gly-Tyr motif in response to environmental stress that can also activate JNK. Such stress includes UV radiation, endotoxin, and hyperosmolarity, as well as proinflammatory cytokines like tumor necrosis factor and interleukin-1 (Freshney et al., 1994; Han et al., 1994; Lee et al., 1994; Rouse et al., 1994; Raingeaud et al., 1995) . ERK is activated by mitogens and survival factors (Cano and Mahadevan, 1995; Cobb and Goldsmith, 1995) . Therefore, p38 and JNK are known as stress-activated protein kinases. Recently, p38 activation has also been implicated in mediating apoptosis in several cell types in various species (Kawasaki et al., 1997; Kummer et al., 1997; Horstmann et al., 1998; Castagné and Clarke, 1999) . However, the role of p38 in apoptotic pathways differs in a cell-type-and stimulation-dependent manner. In the mammalian retina, bovine retinal pigment epithelial cells manifest p38 immunoreactivity, which is activated by lipopolysaccharide or interferon-␥ (Faure et al., 1999) , but the localization and role of p38 in neurons of the mammalian retina remains unclear.
In mammalian retinal ganglion cells (RGCs), as well as in other CNS neurons, axotomy close to the cell body causes retrograde degeneration and delayed RGC death (Aguayo et al., 1983; Villegas-Perez et al., 1988; Thanos et al., 1993) . This form of cell death appears to be apoptotic in nature, similar to programmed cell death during retinal development (Berkelaar et al., 1994; Garcia-Valenzuela et al., 1994; Isenmann et al., 1997) . It has been suggested that optic nerve-axotomized RGCs die because of deprivation of neurotrophic factors from the superior colliculus. Exogenous application of neurotrophic factors such as BDNF and NGF are known to enhance RGC survival after axotomy Peinado-Ramon et al., 1996; Klocker et al., 1997; Yan et al., 1999) . Recently, other studies have reported that the intraocular level of glutamate is elevated after optic nerve axotomy (Yoles and Schwartz, 1998) , and abnormal activation of glutamate receptors is involved in axotomy-induced RGC apoptosis (Russelakis-Carneiro et al., 1996; Yoles et al., 1997 ). Here we demonstrate that p38 is activated in RGCs after optic nerve axotomy and that this activation is in the signaling pathway to RGC apoptosis mediated by NMDA receptordependent neurotoxicity.
MATERIALS AND METHODS
Retrograde labeling of retinal ganglion cells. Adult male L ong-Evans rats weighing 200 -250 gm were obtained from a local breeder and, for all experimental manipulations, were anesthetized with 1-2% isoflurane and 70% N 2 O. RGC s were retrogradely labeled with FluoroGold (hydroxystilbamidine; Molecular Probes, Eugene, OR) to allow accurate counting of cell bodies, as previously described (Vorwerk et al., 1999a,b) .
Rats were anesthetized and placed in a small stereotactic instrument. The skull was exposed and kept dry. The bregma was identified and marked, and a small window was drilled above the right hemisphere, leaving the dura intact. Using a stereotactic measuring device and a Hamilton injector, hydroxystilbamidine solution was injected into four (4) regions of the right superior colliculus using the following coordinates from the bregma (anteroposterior, mediolateral, and depth, all listed in millimeters): (1) Ϫ5.8, ϩ1.0, Ϫ4.4; (2) Ϫ6.5, ϩ0.7, Ϫ4.0; (3) Ϫ6.5, ϩ1.0, Ϫ4.0; and (4) Ϫ7.3, ϩ1.5, Ϫ3.7.
A xotomy. Optic nerve axotomy was performed on the left eye 4 d after retrograde labeling. After incision of the dorsolateral conjunctiva, the lateral extraocular muscle was transected, and the optic nerve was exposed under a stereoscopic microscope. The optic nerve was then transected at a distance of ϳ1 mm from the eye bulb. During the operation, care was taken to avoid damage to the retinal blood supply.
Drug application. Intravitreal injections were performed using a 33 gauge needle attached to a 25 l syringe after pupil dilation with 1% atropine sulfate. The tip of the needle was inserted through the dorsal limbus of the eye under stereomicroscopic visualization. Injections were completed over a period of 1 min. Intravitreal injections of SB203580 (C albiochem, San Diego, CA), M K801 (Research Biochemicals International, Natick, M A) or control solutions (as an equal volume of saline diluent) were performed on operated eyes immediately after axotomy, and repeated 5 and 10 d after axotomy.
Quantification of a xotomized RGC survival and histolog y. At various time points, rats were given an overdose of pentobarbital, and the eyes were removed. The retina was caref ully dissected from the eye, prepared as a flat whole-mount in a 4% paraformaldehyde solution, and examined for stained ganglion cells by epifluorescence microscopy to determine the density. The number of surviving RGCs in experimental and control retinas was determined by counting hydroxystilbamidine-labeled neurons in three standard areas of each retinal quadrant at one-sixth, one-half, and five-sixths of the retinal radius, for a total area of 2.25 mm 2 , as previously described by Kermer et al. (1998) . RGC survival data from each group of animals is presented as the mean density (RGC s/mm 2 ) and SD for n ϭ 3-6 retinas. Statistical significance of the data were determined by an ANOVA followed by a post hoc Dunnett's test. For the histological studies, retinal whole-mounts were prepared and stained by the method of Nissl using cresyl violet (0.1%).
Immunohistochemistr y. After enucleation, the eyes were immersed in fixative composed of 4% paraformaldehyde in PBS, pH 7.4, at 4°C. Ten minutes later, the eyes were hemisected in the fixative, and the anterior segment, lens, and vitreous body were discarded. The remaining posterior eyecup was kept in fresh fixative solution overnight at 4°C. The eyecup was then embedded in paraffin. Sections 5 m in thickness were cut on a microtome and transferred onto gelatin-coated glass slides. After rehydration, sections were treated for 30 min at room temperature with methanol to increase membrane permeability, followed by 4% hydrogen peroxide for 1 hr to block intrinsic peroxidase activity. Then, sections were incubated with 20% normal goat serum (NGS) for 1 hr. After rinsing, the sections were incubated overnight at 4°C in PBS with 0.3% Triton X-100, 1% NGS, and one of the following specific antibodies: 1:1000 anti-p38␣ antibody (Santa Cruz Biotechnology, Santa Cruz, CA), 1:250 anti-phospho-specific p38 (New England BioLabs, Beverly, M A), or 1:50 anti-rat ED1 antibody (Serotec, Oxfordshire, UK). The sections were then incubated with biotinylated anti-IgG (Sigma, St. L ouis, MO) for 2 hr at room temperature. Color development was performed with a Vector AEC substrate kit (Vector Laboratories, Burlingame, CA) or with a Sigma Fast DAB kit. When immunoreactivity was exclusively localized to the nucleus (see Fig. 5C ), counterstaining was needed to define the cell somata, and Meyer Hematoxylin was used.
Immunoblotting. Retinas were homogenized in SDS sample buffer (2% SDS, 0.6% 2-mercaptoethanol, 10% glycerol, and 50 mM Tris, pH 7.2) and centrif uged. After estimation of supernatant protein concentration with a Bio-Rad (Hercules, CA) Protein Assay, aliquots containing 70 g of protein were separated by SDS-PAGE and transferred onto a nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Biotech). The membranes were then blocked with 25 mM Tris-HC l, pH 7.4, 137 mM NaC l, 2.68 mM KC l, and 0.1% T ween 20 containing 5% nonfat milk for 1 hr at room temperature. Membranes were probed with 1:1500 antip38␣ antibody, 1:200 anti-p38␤ antibody (Santa Cruz Biotechnology), or 1:500 anti-phospho-specific p38 according to the instructions of the manufacturer. The antibody-reactive bands were visualized by chemiluminescent detection (ECL western detection kit; Amersham Pharmacia Biotech).
Retinal cell cultures.
Retinal cells were prepared from 6-to 10-d-old L ong-Evans rats as described previously (Leifer et al., 1984) . Briefly, after dissociation in papain, retinal cells were plated on poly-L-lysinecoated glass coverslips in Eagle's minimum essential medium. RGC s were identified by immunocytochemical staining using an anti-Thy-1 antibody (2G12), which is specific among rat retinal cells for the ganglion cells (Leifer et al., 1984) .
Assessment of NMDA-induced apoptosis in cultured RGCs. To induce predominantly apoptosis Dreyer et al., 1995) , retinal cell cultures were exposed to 200 M NMDA/5 M glycine for 18 hr in high calcium (3 mM) medium. For specific labeling of RGC s, the cultures were incubated with anti-Thy-1 antibody for 1 hr. After three washes with PBS, cells were incubated in goat anti-mouse IgG-FI TC for 1 hr. For assessment of apoptosis, retinal cells were fixed, permeabilized, and stained with 20 g /ml propidium iodide for 5 min, as previously described . Briefly, coverslips containing the cells were washed once with PBS and permeabilized with 85% methanol for 10 min. After another wash with PBS, coverslips were fixed in acetone for 5 min and subsequently stained with propidium iodide for 5 min in the dark. The coverslips were then mounted on glass slides in glycerol:PBS (1:1), and visualized under epifluorescence microscopy. Apoptotic nuclei were scored in cells that were also stained by anti-Thy-1 and expressed as a fraction of total RGC s.
RESULTS

Effects of axotomy on RGCs
RGCs labeled retrogradely with hydroxystilbamidine showed a characteristically fine-dotted pattern of fluorescence in the perikarya (Fig. 1 A) . One day after axotomy, no remarkable change in the fluorescence pattern of RGCs was seen compared to that of controls (Fig. 1 B) . RGC density, as assessed by the number of fluorescently labeled cells, began to decline between 4 and 7 d after axotomy (Fig. 1C) . By 14 d, a substantial number of fluorescently labeled RGCs appeared to have been lost (Fig. 1 D) . Additionally, at 7-14 d after axotomy, we observed a number of other cells labeled with hydroxystilbamidine in the ganglion cell layer (GCL) and other retinal layers, although the pattern of fluorescence was quite different from that of RGCs (Fig. 1C,D , white arrows). These cells had small somata and fine tortuous processes, and were morphologically typical of microglia (for specific immunostaining, see below). In the adult rat retina, microglial cells phagocytose the debris of degenerating RGCs (Perry et al., 1983) and thus can become fluorescently labeled (Thanos et al., 1992 .
Morphologically, in whole-mounted retinas stained with cresyl violet, GCL of unlesioned control retinas manifest no apoptotic profiles or pyknotic nuclei (Fig. 2 A) . In contrast, by 10 d after axotomy, multiple degenerating cell bodies with pyknotic nuclei were apparent in the GCL, and the cell density in this layer appeared to be greatly diminished (Fig. 2 B) .
When hydroxystilbamidine fluorescence in the GCL was quantified (Fig. 3) , in unlesioned control retinas the mean RGC density was 2533 Ϯ 104 cells/mm 2 (mean Ϯ SD). Within 14 d of axotomy, the mean RGC density decreased to 348 Ϯ 107 (14% of control, Fig. 3 ).
Activation of p38 in RGCs after optic nerve axotomy
We initially investigated which isoform of p38 is predominant in the adult rat retina. In control retinas, p38␣ displayed strong immunoreactivity by immunoblotting (Fig. 4 A, left lane) , whereas p38␤ was virtually undetectable (Fig. 4 A, lanes 2, 3) . We next used a second anti-p38␤ antibody for immunoblotting (the gift of Dr. J. Han, The Scripps Research Institute), but it, too, did not detect p38␤ immunoreactivity in control retinas or after axotomy (data not shown). Immunoblotting also revealed that p38 was not phosphorylated/activated in control retinas (Fig. 4 B, top panel) . Phosphorylated p38 was first detected 12 hr after axotomy, reached a maximum at 1 d, and then slowly decreased. By 14 d, phosphorylated p38 had virtually disappeared (Fig. 4 B, top panel ) . Nonetheless, total p38 immunoreactivity (including both phosphorylated and unphosphorylated forms) did not change substantially after axotomy (Fig. 4 B, bottom panel ) . This result was expected because many cell types (see below) contain unactivated (unphosphorylated) p38, and RGCs comprise only 1% of the retinal population. Importantly, 1 d after axotomy, when p38 phosphorylation had reached its maximum, neither RGC density nor the pattern of staining with hydroxystilbamidine had yet changed (Fig. 1 B) . Moreover, when phosphorylated p38 reached . A, Immunoreactivity of p38 isoforms in adult rat retinas by immunoblotting. Strong immunoreactivity for p38␣ was present in control retinas (left lane), whereas p38␤ was virtually undetectable in control retinas (middle lane) and 24 hr after axotomy (right lane). B, Temporal profiles of p38 activity by immunoblotting. Total p38␣ immunoreactivity (including both phosphorylated and nonphosphorylated forms) did not change after axotomy (bottom panel ). p38 was not phosphorylated in control retinas, but phosphorylation was detected 12 hr after axotomy and reached a maximum at 24 hr before slowly decreasing (top panel). By 14 d after axotomy, phosphorylated p38 immunoreactivity had essentially disappeared.
its maximum, no p38␤ immunoreactivity was observed (Fig. 4 A,  right lane) , in contrast to the presence of p38␣.
In the next series of experiments, we investigated the localization of p38␣ and phosphorylated/activated p38 in the adult rat retina. In control retinas, p38␣ immunoreactivity was seen in virtually all cells in the GCL, inner plexiform layer (IPL), outer plexiform layer (OPL), and in some cells in the proximal portion of the inner nuclear layer (INL; Fig. 5A, control ) . However, no cells in control retinas stained positively for phosphorylated/ activated p38 (Fig. 5B, control ) . In contrast, 1 d after axotomy, phosphorylated/activated p38 localized to cell nuclei in the GCL layer (Fig. 5B,C, arrows) . Nonetheless, the distribution of total p38␣ immunoreactivity did not change (Fig. 5A, 1 day) . By 14 d after axotomy, when both phosphorylated/activated p38 immunoreactivity and most RGCs themselves were gone (Fig. 5B, 14 days), p38␣ total immunoreactivity was still observed in the GCL, IPL, and OPL, and in some cells in the proximal portion of the INL (Fig. 5A,B, 14 days) .
Previously, Walton et al. (1998) had demonstrated that microglial cells, rather than neurons, manifest p38 activation after global forebrain ischemia. Therefore, we visualized activated microglia with anti-ED1 antibody (Fig. 5D ). One day after axotomy, ED1-positive cells had a different distribution compared to the p38-activated cells (Fig. 5D, black arrows) . Virtually none of the microglial cells, by both histological and morphological criteria, coincided with cells that stained positively with anti-phosphorylated p38 (Fig. 5B, 1 day) .
Effect of p38 inhibition on survival of axotomized RGCs
After demonstrating that p38␣ was activated/phosphorylated in the nuclei of axotomized RGCs during an early phase of apoptosis, we next examined whether treatment with SB203580, an inhibitor of p38 Cuenda et al., 1995) , could prevent axotomy-induced RGC apoptosis. SB203580 was administered intravitreally at the time of axotomy and repeated at 5 and 10 d. Assayed 14 d after axotomy, SB203580 increased the number of surviving RGCs in a dose-dependent manner (Fig. 6) . A significant degree of neuroprotection was observed after injection of as little as 0.2 nmol of SB203580, corresponding to an intravitreal concentration of 1.6 M, given the volume of the rat vitreous has been reported to be ϳ120 l (Hughes, 1979) .
Involvement of the p38 signaling pathway in NMDAinduced neuronal apoptosis
We next investigated if glutamate neurotoxicity via activation of the NMDA receptor could effect apoptosis via the p38 signaling pathway in RGCs. To address this question, we first examined the effects of SB203580 on NMDA-induced RGC apoptosis in vitro. Treatment with 1 M SB203580 significantly increased the survival of RGCs in the face of an NMDA exposure capable of causing apoptosis (Fig. 7) . This finding suggested that p38 activation is involved in RGC apoptosis induced by NMDA. Then, we tested the effect on axotomy of the noncompetitive NMDA receptor antagonist MK801 in vivo. MK801 was injected into the vitreous in the same manner as SB203580. MK801 not only increased the number of surviving RGCs 14 d after axotomy (Fig.  8 A) , but also inhibited p38 phosphorylation/activation in a dosedependent manner (Fig. 8 B) . The addition of SB203580 to MK801 did not offer further protection above that of MK801 alone in this paradigm (Fig. 8 A) .
DISCUSSION
In the present study, we demonstrate that the p38 MAP kinase signaling pathway is involved in RGC apoptosis after axotomy. Previous reports have described the time course of survival of RGCs after axotomy Villegas-Perez et al., 1993; Peinado-Ramon et al., 1996; Klocker et al., 1997) . In general, the loss of RGCs is more severe when the optic nerve is transected close to the eye globe (Villegas-Perez et al., 1993) . In our studies we found that after axotomy near the eye, the density of RGCs remained approximately constant for ϳ4 d, and then ϳ86% of RGCs died over the ensuing 10 d. This time course is similar to that of other reports (Peinado-Ramon et al., 1996; Klocker et al., 1997; Koeberle and Ball, 1998) . We next studied the time course of p38 activity after axotomy but preceding cell death.
p38 has four isoforms, designated p38␣ (Han et al., 1994; Lee et al., 1994) , p38␤ , p38␥ (Lechner et al., 1996; Li et al., 1996) , and p38␦ (Jiang et al., 1997; Wang et al., 1997) . Relatively little is known about the potential role of p38␥ and p38␦ in apoptosis. However, p38␣ and p38␤ have been shown to be involved in the apoptotic pathway in several cell types, including neurons, at least in vitro (Kawasaki et al., 1997; Kummer et al., 1997 ). Here we demonstrate strong immunoreactivity for p38␣, but not p38␤ in the normal retina. These control retinas, however, did not manifest phosphorylated/activated p38 activity. After axotomy, anti-phospho-p38 immunoreactivity, signifying activated p38␣, was visualized only in the GCL. Because the phosphorylated/activated p38 disappeared from the GCL as the RGCs died, it is likely that this cell type contained the activated form of p38.
The question arises, however, why total p38 activity did not appear to decrease in the retina after the demise of the RGCs after axotomy. In adult rats, the population of RGCs represents Ͻ1% of total retinal cells. Additionally, 40 -50% of the cells in the rodent GCL are displaced amacrine cells rather than RGCs (Perry, 1981) . Fourteen days after axotomy, total p38 immunoreactivity was still seen in the GCL, IPL, OPL, and in some cells in the proximal portion of the inner nuclear layer (INL; Fig. 5A ). It is likely, however, that the p38 immunoreactivity that remained 2 weeks after axotomy represented staining of amacrine cells, a population that far outnumbers the RGCs. In fact, 14 d after axotomy phosphorylated/activated p38 immunoreactivity had disappeared as had the RGCs. Thus, 2 weeks after axotomy total p38 immunoreactivity reflected mainly the inactive (unphosphorylated) p38 that was present in the amacrine cells. In contrast, phosphorylated/activated p38 was observed only in cells injured by axotomy, i.e., the RGCs, and only at earlier time points.
Recently, Walton et al. (1998) reported that phosphorylated p38 increases in activated microglia after forebrain ischemia. We therefore studied p38 activity in microglia in the retina. After optic nerve axotomy, microglia are known to be activated and, in our study, some became fluorescent by phagocytosis of degenerating hydroxystilbamidine-labeled RGCs (Thanos et al., 1992 . However, we found that few if any microglia were labeled by anti-phospho-p38 compared to RGCs.
Next, we investigated if a p38 antagonist could protect RGCs from apoptosis after axotomy. 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl) imidazole (SB203580) is an inhibitor of p38 MAP kinase (Cuenda et al., 1995) . Among the various p38 isoforms, p38␣ and p38␤ are sensitive to this pyridinyl imidazole derivative, whereas p38␥ and p38␦ are not (Cuenda et al., 1997) . In general, pyridinylimidazoles, such as SB203580, inhibit p38 activity by blocking the ATP-binding site (Wilson et al., 1997) . Thus, SB203580 does not inhibit the phosphorylation of p38. It is important to note that at ϳ10-fold higher concentrations of SB203580 than used here to protect RGCs (we used 1.6 M in vivo in Fig. 6 and 1.0 M in vitro in Fig. 7) , this drug can also inhibit JNK (Harada and Sugimoto, 1999) . Similar to p38, JNK can also participate in apoptotic signaling in some cell types. However, at ϳ1 M SB203580 appears to be relatively specific for p38 (Harada and Sugimoto, 1999) , although we acknowledge that another mode of action of the drug cannot be completely eliminated. Additionally, we demonstrated that p38 activation/phosphorylation preceded RGC apoptosis and that pharmacological prevention of death with another drug (an NMDA receptor antagonist, see below) also prevented p38 activation/phosphorylation. Taken together, therefore, our results suggest that p38␣ activation in RGCs occurs early after axotomy and plays an important role in apoptosis.
Next we investigated possible upstream pathways for p38 activation leading to RGC apoptosis. RGC apoptosis after optic nerve axotomy is thought to occur, at least in part, because of a lack of neurotrophic factor support from the superior colliculus , Peinado-Ramon et al., 1996 Klocker et al., 1997; Yan et al., 1999) and also because of excessive glutamate levels possibly caused by the injury (Yoles and Schwartz, 1998) . In the present study, we focused on glutamate neurotoxicity because p38 had been reported to participate in neuronal cell death pathways triggered by glutamate in in vitro cerebellar granule cell, striatal, and hippocampal models (Kawasaki et al., 1997; Vincent et al., 1998; Mukherjee et al., 1999) . Additionally, RGCs were the first neurons to be shown to be vulnerable to glutamate-induced cell death (Lucas and Newhouse, 1957) . Initially, we prepared cultured RGCs to test whether p38 MAP kinase activation is involved in NMDA-induced RGC apoptosis. Treatment with SB203580 protected RGCs from NMDA-induced apoptosis, suggesting that p38 activation plays an important role in this form of RGC death. Furthermore, intravitreal administration of the noncompetitive NMDA receptor antagonist MK801 prevented RGC apoptosis caused by axotomy in our study as well as in other reports (Russelakis-Carneiro et al., 1996; Yoles et al., 1997) . Importantly, in our axotomy model, MK801 also inhibited phosphorylation of p38 in a dose-dependent manner, suggesting that p38 activation after axotomy is mediated by stimulation of NMDA receptors.
Recently, p38 inhibitors have been shown to be effective in animal models of arthritis, bone resorption, and endotoxic shock (Badger et al., 1996) , and several human clinical trials are currently in progress for these entities. Optic nerve axotomy permits rapid analysis of RGC death and is therefore a valuable model for diseases producing RGC apoptosis, including glaucoma. We and our colleagues recently reported that glutamate neurotoxicity may mediate, at least in part, glaucomatous damage to RGCs (Dreyer et al., 1996; Dkhissi et al., 1999; Dreyer and Lipton, 1999; Vorwerk et al., 1999b ). Here we show that inhibition of p38 MAP kinase activity can ameliorate glutamate-related RGC apoptosis in vitro and axotomy-induced RGC death in vivo. In fact, this represents the first in vivo model with a p38 inhibitor to show efficacy in the adult mammalian central nervous system. Therefore, we speculate that p38 inhibitors may be potentially useful for the treatment of retinal diseases such as glaucoma.
